Ultragenyx Pharmaceutical (RARE) Short-term Investments (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Short-term Investments for 14 consecutive years, with $238.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Short-term Investments fell 35.22% year-over-year to $238.0 million; the TTM figure through Mar 2026 stood at $238.0 million (down 35.22% YoY), while the FY2025 annual figure was $259.0 million, down 40.6% from the prior year.
• Short-term Investments slipped to $238.0 million in Q1 2026 per RARE's latest filing, from $259.0 million in the prior quarter.
• Across five years, Short-term Investments topped out at $543.6 million in Q1 2023 and bottomed at $2.8 million in Q4 2022.
• Historically, Short-term Investments has averaged $328.3 million across 5 years, with a median of $367.4 million in 2025.
• Annual changes were most pronounced in 2022 — Short-term Investments sank 84.83% — and 2024, when it jumped 13507.99%.
• Ultragenyx Pharmaceutical's Short-term Investments stood at $2.8 million in 2022, then increased by 14.14% to $3.2 million in 2023, then surged by 13507.99% to $436.0 million in 2024, then tumbled by 40.6% to $259.0 million in 2025, then decreased by 8.11% to $238.0 million in 2026.
• Business Quant data shows RARE's Short-term Investments at $238.0 million in Q1 2026, $259.0 million in Q4 2025, and $222.7 million in Q3 2025.